Quotes 5-day view Delayed Japan Exchange
05/12/2022
05/13/2022
05/16/2022
05/17/2022
05/18/2022
Date
3616(c)
3671(c)
3661(c)
3679(c)
3690(c)
Last
7 106 700
5 973 700
3 785 700
3 689 500
5 595 100
Volume
-3.19%
+1.52%
-0.27%
+0.49%
+0.30%
Change
Estimated financial data (e) JPY USD
Sales 2022
3 490 B
26 982 M
26 982 M
Net income 2022
239 B
1 847 M
1 847 M
Net Debt 2022
3 299 B
25 501 M
25 501 M
P/E ratio 2022
24,0x
Yield 2022
4,89%
Sales 2023
3 561 B
27 533 M
27 533 M
Net income 2023
311 B
2 403 M
2 403 M
Net Debt 2023
2 767 B
21 390 M
21 390 M
P/E ratio 2023
18,5x
Yield 2023
4,89%
Capitalization
5 679 B
43 902 M
43 902 M
EV / Sales 2022
2,57x
EV / Sales 2023
2,37x
Nbr of Employees
47 099
Free-Float
97,2%
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United...
Ratings of Takeda Pharmaceutical Company Limited
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
05/12 Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Project.. MT
05/11 Takeda Pharmaceutical's FY22 Attributable Profit Falls 39% MT
05/11 GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
05/11 TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q4 2022 Earnings Call, May 11, 2022CI
05/11 TRANSCRIPT : Takeda Pharmaceutical Company Limited, 2022 Earnings Call, May 11, 2022CI
05/11 Takeda Pharmaceutical Posts Higher Profit, Revenue in Fiscal 2021 MT
05/11 Takeda Pharmaceutical Posted Fourth-Quarter Net Loss DJ
05/11 Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022 BU
05/11 Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the F.. CI
05/11 Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 20.. CI
05/11 Takeda Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended .. CI
04/29 OncoSec Medical Names Robert Arch CEO; Shares Rise Early MT
04/29 HilleVax Shares Gain Ground in Trading Debut After Upsized IPO DJ
04/28 CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient .. AQ
04/27 Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories AQ
News in other languages on TAKEDA PHARMACEUTICAL COMPANY LIMITED
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
COVID vaccine maker Moderna flags Japan ambition with sumo sponsorship
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
3 679,00 JPY
Average target price
4 302,67 JPY
Spread / Average Target
17,0%
Please enable JavaScript in your browser's settings to use dynamic charts.